Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Qilu Pharma In-licenses Bladder Cancer Drug in $35 Million Deal

publication date: Jul 31, 2020

Qilu Pharma of Jinan in-licensed Greater China rights to a treatment for bladder cancer from Seseen Bio of the US in a $35 million agreement. Qilu will also have global manufacturing rights to Vicineum, a proposed treatment for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). Qilu will make an upfront payment of $12 million and be responsible for up to $23 million in technology transfer and milestone payments, plus royalties. Vicineum is a locally administered fusion protein that has completed a Phase III trial for NMIBC. More details....

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China